Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
2022 Annual Report_spreads
…research, community support and stewardship of funds. Since the CMTA instituted its Strategy to Accelerate Research (STAR) in 2008, the field of CMT research has grown by leaps and bounds….
CMTAreportspring24FINALwebSPREADS
…STAR (Strategy to Accelerate Research), our premier research initiative, as well as important community initiatives like Camp Footprint, Patient/Research Conferences, and educational programs. All of these programs require steady, reliable…
CMTAWinter2023webspreads
…The CMTA Patient & Research Summit covered all my interests. I felt honored to be in the presence of the top researchers and scientists spearheading the research for a cure…
DNA-Based Therapeutics: A Promising Future for CMT2E Treatment
Researchers at the University of Miami, supported by the Charcot-Marie-Tooth Association (CMTA) and its Strategy To Accelerate Research (STAR) and led by CMTA-STAR Advisory Board member Mario Saporta, MD, PhD,…
Vera Fridman, MD joins the CMTA STAR Advisory Board
…and Associate Director of Medical Student Education for the Department of Neurology. Dr. Fridman has a long-standing clinical and research interest in peripheral neuropathy, her research to date has focused…
CMT2F Natural History Study Nears Full Recruitment as Biomarker Analysis Begins
…Iowa coordinator at CMTRes@healthcare.uiowa.edu to become the final participant. Register with Patients as Partners in Research Today Not yet registered with Patients as Partners in Research? Click the button below…
CMTA-INC Strategic Alliance Announces the 2025 Inherited Neuropathy Fellowship
…experience in all aspects of clinical research related to inherited neuropathies. Conduct an in-depth research project aligned with their specific interests. Train at one of the INC’s premier research centers,…
CMTA Alliance Partner, NMD Pharma, Announces Encouraging Data with Implications for CMT
…Forsey, Ph.D., CMTA chief research officer. “NMD Pharma’s pioneering research not only sheds light on novel therapeutic avenues but also underscores the interconnectedness of neuromuscular disorders. We eagerly anticipate the…
2023 CMTA-STAR Celebrating our Collective Achievements
Significant Research Investment Made in 2023: We are excited to share that in 2023, the CMTA has ongoing and committed investments of $5,000,00 in research dedicated to finding effective treatments…
Alliance Partner NMD Pharma A/S Launches Phase II SYNAPSE-CMT Trial with First Patient Dosed at CMTA Center of Excellence
…soon contact our Patients as Partners in Research who match the study criteria for NMD Pharma’s SYNAPSE-CMT trial. CMTA will contact only those who consent to receive research opportunity notifications….